BPC-157

A stable gastric pentadecapeptide, BPC-157 (Body Protection Compound-157) is a 15-amino-acid fragment studied for tendon, ligament, muscle and nerve healing through angiogenic and growth-factor pathways.

What it is

BPC-157 is a synthetic pentadecapeptide: a chain of fifteen amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). It is described as a partial sequence of a larger cytoprotective protein isolated from human gastric juice, which is the origin of its name, Body Protection Compound. Unlike many peptides it is notably stable in gastric acid, a property that first drew the attention of the Sikiric group at the University of Zagreb, who have published the bulk of the preclinical literature on the molecule.

The compound belongs to the broad class of cytoprotective and regenerative peptides. It is supplied as a lyophilized free-acid powder and is a frequent subject in tissue-repair research spanning tendon, ligament, muscle, nerve, bone and gut models. Supplied strictly for laboratory research use only, not for human or veterinary use.

How it works

The most consistently reported mechanism is the promotion of angiogenesis. In endothelial models BPC-157 upregulates vascular endothelial growth factor receptor-2 (VEGFR2) at both the mRNA and protein level and drives receptor internalization, without raising VEGF-A itself. This activates the downstream VEGFR2 to Akt to eNOS cascade, increasing production of nitric oxide (NO) in endothelial cells. The nitric-oxide system is central to its reported healing effects: work from the Sikiric group first showed NO generation contributing to its gastric cytoprotection, and later studies tied NO modulation to repair across multiple injured tissues.

In vascular preparations BPC-157 activates the Src-Caveolin-1-eNOS pathway, producing concentration- and nitric-oxide-dependent vasomotor effects. In connective-tissue models it engages the cytoskeletal and adhesion machinery directly: in cultured Achilles tendon fibroblasts it induced F-actin formation and dose-dependently increased phosphorylation of FAK and paxillin, the signalling proteins that govern cell migration and adhesion. Separately, BPC-157 was shown to upregulate the growth-hormone receptor in tendon fibroblasts, sensitising those cells to growth hormone and amplifying downstream JAK2 signalling and proliferation.

What the research shows

The evidence base is predominantly preclinical, drawn from rodent injury models and cultured cells. The most quantified in-vitro findings come from the Chang group, who reported that BPC-157 raised growth-hormone-receptor expression in tendon fibroblasts up to sevenfold over three days and that it accelerated tendon-explant outgrowth and dose-dependently increased fibroblast migration. Whole-animal work from the Sikiric group reported improved macroscopic, microscopic and functional recovery in crushed and transected muscle and in injured tendon.

Safety signals in the literature

Rodent toxicity work from the Sikiric group has repeatedly reported a wide margin between active doses and any observed toxicity, and no lethal dose was established in those studies. The main open question raised in recent reviews concerns its pro-angiogenic action: because BPC-157 promotes new blood-vessel formation through VEGFR2, commentators have flagged a theoretical concern about effects on angiogenesis-dependent processes, an issue discussed in the 2025 Sikiric and Jozwiak exchange in Pharmaceuticals. This remains a matter of scientific debate rather than a documented adverse finding.

Side Effects

There is no established human side-effect profile for BPC-157. No controlled clinical trials have characterized its safety or efficacy, so almost all evidence comes from rodent and other animal work, much of it from the original Sikiric group. The handful of small human pilot studies reported no adverse events, but they were tiny and underpowered, and independent replication is limited. The effects below are drawn from preclinical toxicology, theoretical mechanism-based concerns, and anecdotal use, not from established human safety data.

Taken together, the animal toxicology looks favorable and no lethal dose has been established, but that is not evidence of human safety. Because no controlled human trials have been completed, the real-world side-effect profile of BPC-157 in people remains unknown, and the angiogenesis-related and other mechanism-based concerns are unresolved.

At a glance

The sequence is GEPPPGKPADDAGLV (molecular formula C₆₂H₉₈N₁₆O₂₂), catalogued under PubChem CID 9941957.

Dosing

There is no approved or established human dose for BPC-157, and no controlled human dosing trial has defined one. Every figure below is a dose used in animal studies, mostly rats and dogs, reported in the primary literature. They are provided as educational context about what researchers administered, not as guidance for human use. Converting these animal doses to humans is not validated.

These are animal-study doses, and they span a very wide range, from nanograms to milligrams per kilogram, depending on the model and route. No validated human dose exists, and animal-to-human conversion for BPC-157 has not been established. This information is provided for laboratory research and educational reference only.

Preparing it

The vial ships as a lyophilized powder and is reconstituted with bacteriostatic water (or sterile water for single-session work) before use. Choose a diluent volume that gives a concentration convenient to read on a U-100 syringe. See reconstitution for the method and the concentration formula for working out the diluent. Store the sealed vial cold and reconstituted material at 2-8 C.

Where to go next

Last updated on July 3, 2026